Triple

T23399721
Position Surface form Disambiguated ID Type / Status
Subject ELN E559469 entity
Predicate associatedCompany P629 FINISHED
Object Elan Pharmaceuticals NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Elan Pharmaceuticals | Statement: [ELN, associatedCompany, Elan Pharmaceuticals]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Elan Pharmaceuticals
Context triple: [ELN, associatedCompany, Elan Pharmaceuticals]
  • A. Elan Pharmaceuticals chosen
    Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
  • B. Portola Pharmaceuticals
    Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
  • C. Gland Pharma
    Gland Pharma is an Indian pharmaceutical company specializing in injectable formulations and contract manufacturing for global markets.
  • D. United Therapeutics
    United Therapeutics is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension and other serious cardiopulmonary conditions.
  • E. Idun Pharmaceuticals
    Idun Pharmaceuticals is a biotechnology company focused on developing therapies that regulate cell death pathways, particularly apoptosis, for the treatment of various diseases.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e24549610c8190a069d6411ce5f661 completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1a4dedfcc8190ab93cec3c3d15c53 completed April 29, 2026, 6:27 a.m.
Created at: April 17, 2026, 5:37 p.m.